1. FORTISSIMO study
Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide fixed full-dose combination
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

2. Objectives
Evaluate the safety and efficacy of the fixed-dose combination perindopril arginine/indapamide (10/2.5 mg) in reaching the blood pressure target
In patients with uncontrolled hypertension
With previous treatment: fixed or free combination of renin-angiotensin-aldosterone system (RAAS) inhibitors + hydrochlorothiazide (HCTZ)
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

3. Design and Methods
Open, prospective, multicenter, observational, noncomparative study
Inclusion criteria: uncontrolled hypertension ( mm Hg)
2120 hypertensive ambulatory patients in 35 regions of Russia
12-week study (5 visits)
Switch to drug combination perindopril/indapamide (10/2.5 mg)
Assessment of:
Office blood pressure dynamics
Blood and urine assays
Quality of life
Treatment compliance
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

4. Results – Blood pressure
Blood pressure significantly decreased over time
After 3 months of treatment, 84% of patients reached the blood pressure target
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

5. Results - Tolerability
Treatment compliance significantly increased
Only 4% of patients had adverse effects
Biochemical markers showed no negative changes
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

6. Conclusion
Rapid and sustained effect with the drug combination perindopril/indapamide (10/2.5 mg) in patients with uncontrolled hypertension
84% of patients reached the blood pressure target
Treatment: good tolerability
Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.